Subscribe to our Newsletters !!


    Biocon gets drug controller’s gesture for CytoSorb gadget to treat basic COVID-19 patients

    Biocon on May 27 said its auxiliary Biocon Biologics has gotten the Drugs Controller General of India (DCGI) endorsement for extracorporeal blood refinement (EBP) gadget CytoSorb to diminish ace fiery cytokines levels in affirmed COVID-19 patients admitted to the emergency unit with affirmed or inescapable respiratory disappointment. Biocon Biologics has been conceded the permit for

    Biocon’s accomplice Equillium plans Itolizumab’s worldwide clinical preliminary for COVID-19

    Biocon’s partner Equillium has said it is planning to conduct a global randomised controlled clinical trial of Itolizumab in COVID-19 patients, for the American biotech firm will record a US investigational new drug application (IND). Itolizumab, which is used for the treatment of psoriasis, is repurposed for COVID-19, as it regulates the production of inflammatory

    Minitsry of Health rules against incorporating Itolizumab in clinical administration convention for COVID-19

    The National Task Force on COVID-19 has ruled against incorporating Itolizumab medicate in clinical administration conventions for rewarding the malady despite the fact that the DCGI has affirmed its “confined crisis use” in contaminated patients, official sources said. Considering the neglected clinical needs in COVID-19, Itolizumab, a previously endorsed medication of Biocon, utilized for rewarding